palbociclib&fulvestran-progression of ER+, HER2- metastatic bc

Anonymous

palbociclib&fulvestran-progression of ER+, HER2- metastatic bc

besa

http://medicalxpress.com/news/2016-03-drug-combina...

"The combination - of a first-in-class targeted drug called palbociclib, and the hormone drug fulvestrant - slowed cancer growth in around two thirds of women with advanced forms of the most common type of breast cancer.

The combination allowed many women with metastatic hormone-receptor-positive, HER2-negative cancer to delay the start of chemotherapy, which is the traditional treatment option in these patients once hormone drugs have stopped working."...

"Women in the palbociclib plus fulvestrant group took a median of 9.5 months to progress, as measured by CT and MRI scans, compared with 4.6 months in the placebo group.

Some 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.

Some 19 per cent in the palbociclib plus fulvestrant group had a decrease in tumour size compared with 9 per cent in the placebo plus fulvestrant group."

Heidihill

67% with clinical benefit is something to celebrate!